Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 12;289(44):30538–30555. doi: 10.1074/jbc.M114.600833

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 4. — Vehicle control (left) and short-term RXR agonist treatment (right) effects on ABCA1 levels, apoE lipoprotein association, and apoE/Aβ complex levels in E3FAD-CX, E4FAD-CX, and E3FAD-HP. EFAD mice were treated with Bex (100 mg/kg/day), LG (104 mg/kg/day, equimolar to Bex), or vehicle control (VC) from 5.75 to 6 months by daily gavage (T1). In E3FAD-CX, E4FAD-CX, and E3FAD-HP, markers of indirect target engagement include the following: A and B, ABCA1 (WB and TBSX). Mechanistic pharmacodynamics include the following: C and D, TBSX-apoE (ELISA); and E and F, soluble apoE/Aβ complex (ELISA, TBS) were measured. Note: RXR agonists induce no beneficial effects in E3FAD-CX or E4FAD-CX. Data were analyzed by one-way ANOVA followed by Tukey's multiple comparison post hoc analysis. n = 6. *, p < 0.05 (as shown, left); *, p < 0.05 versus VC (right); #, p < 0.05 Bex versus LG (right).